Italy Nuclear Imaging Market Size and Share
Market Overview
| Study Period | 2020 - 2031 |
|---|---|
| Base Year For Estimation | 2025 |
| Forecast Data Period | 2026 - 2031 |
| Market Size (2026) | USD 309.88 Million |
| Market Size (2031) | USD 426.93 Million |
| Growth Rate (2026 - 2031) | 6.62 % CAGR |
| Market Concentration | Medium |
Major Players *Disclaimer: Major Players sorted in no particular order. Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. |
Italy Nuclear Imaging Market Analysis by Mordor Intelligence
Italy nuclear imaging market size in 2026 is estimated at USD 309.88 million, growing from 2025 value of USD 290.65 million with 2031 projections showing USD 426.93 million, growing at 6.62% CAGR over 2026-2031. Robust oncology demand, swift adoption of hybrid PET/CT and SPECT/CT platforms, and steady public-private spending on cyclotron-based radioisotope capacity anchor this upward trajectory. Northern regions capture a disproportionate share of new installations, leveraging denser hospital networks and favorable Servizio Sanitario Nazionale (SSN) tariffs to accelerate procedure volumes. Supply-chain stress linked to overseas Mo-99/Tc-99m reactors keeps domestic isotope innovation front-and-center, with ENEA’s SORGENTINA-RF and INFN’s LARAMED initiatives aiming to curb import reliance. Meanwhile, equipment vendors intensify competitive positioning through R&D-backed product launches and acquisitions that bundle hardware with theranostic tracers.
Key Report Takeaways
- By product category, equipment led with 63.55% of Italy nuclear imaging market share in 2025, radioisotopes are projected to post a 6.75% CAGR through 2031, the fastest among all categories.
- By application, oncology commanded 38.30% share of the Italy nuclear imaging market size in 2025, neurology is projected to expand at a 7.08% CAGR between 2026-2031.
- By end user, hospitals accounted for 71.76% share of the Italy nuclear imaging market size in 2025.
Italy Nuclear Imaging Market Trends and Insights
Driver Impact Analysis
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline | |||
|---|---|---|---|---|---|---|
Rising incidence of cancer & CVD Rising incidence of cancer & CVD | +1.8% | National, concentrated in Northern Italy | Medium term (2-4 years) | (~) % Impact on CAGR Forecast:+1.8% | Geographic Relevance:National, concentrated in Northern Italy | Impact Timeline:Medium term (2-4 years) |
Growing adoption of hybrid PET/CT & SPECT/CT Growing adoption of hybrid PET/CT & SPECT/CT | +1.5% | Northern Italy, expanding to Central regions | Short term (≤ 2 years) | |||
Favorable reimbursement framework (SSN tariffs) Favorable reimbursement framework (SSN tariffs) | +1.2% | National coverage with regional variations | Long term (≥ 4 years) | |||
Increase in public-private investment for nuclear-medicine suites Increase in public-private investment for nuclear-medicine suites | +1.0% | Northern Italy, selective Southern expansion | Medium term (2-4 years) | |||
Expansion of theranostic radioisotope production in Northern Italy Expansion of theranostic radioisotope production in Northern Italy | +0.8% | Northern Italy with national distribution | Long term (≥ 4 years) | |||
Adoption of cyclotron-based Ga-68 generators in regional radiopharmacies Adoption of cyclotron-based Ga-68 generators in regional radiopharmacies | +0.6% | Northern Italy, gradual national rollout | Medium term (2-4 years) | |||
| Source: Mordor Intelligence | ||||||
Rising Incidence of Cancer & CVD
New cancer diagnoses in Italy climbed to 390,700 in 2022, up 14,100 from 2020, with breast, colorectal, and lung cancers topping incidence charts. Mortality projections for 2025 signal a 3.5% national decline, yet aging cohorts continue to push demand for precise staging and therapy monitoring through PET/CT imaging. Hybrid modalities now influence treatment decisions in more than 42% of differentiated thyroid carcinoma cases, highlighting clinical reliance on molecular imaging. Cardiovascular disease persists as the primary mortality cause, and Tc-99m SPECT remains routine for perfusion assessment, reinforcing baseline procedure volumes.
Growing Adoption of Hybrid PET/CT & SPECT/CT
Italian participation in Europe-wide multimodality imaging surveys shows steady acceleration of PET/CT rollouts, with 18F-FDG dominating tracer use. University of Padua researchers recorded 100% sensitivity and 96% accuracy for [18F]FDG PET/MRI in hepatocellular carcinoma surveillance after liver transplantation, outperforming conventional protocols. A 502-patient multicenter trial demonstrated that segmental PET/CT lowers radiation dose without diagnostic compromise in solitary pulmonary nodules, supporting guideline updates. Northern centers advance niche tracers such as 64CuCl2 for bladder cancer staging, reinforcing regional leadership.
Favorable Reimbursement Framework
AIFA oversight ensures nuclear medicine procedures appear in national tariff lists, safeguarding predictable payback for hospitals across Italy. The EUR 15.62 billion National Recovery and Resilience Plan earmarks digital infrastructure and primary-care upgrades from 2021-2026, indirectly smoothing patient pathways to molecular imaging. Decentralized SSN governance still causes tariff variation, but transparency lists narrow price dispersion and support capital planning for hybrid scanners. Complementary funds of EUR 2.387 billion further finance hospital refurbishments, prompting energy-efficient equipment replacement cycles.
Increase in Public-Private Investment for Nuclear-Medicine Suites
Capital inflows intensify in Northern corridors, exemplified by Bracco Imaging’s EUR 80 million Hexagon manufacturing facility that triples ultrasound-contrast output. The government cleared Novartis’s EUR 80 million expansion in Torre Annunziata to scale pharmaceutical packaging by 2025, part of a South-oriented economic rejuvenation plan. GE HealthCare heads the EUR 25.3 million Thera4Care consortium, uniting 29 partners in isotope-production standardization. Parallel nuclear-energy joint ventures among Enel, Leonardo, and Ansaldo Energia may yield synergies for medical isotope supply.
Restraint Impact Analysis
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline | |||
|---|---|---|---|---|---|---|
High equipment capital & maintenance costs High equipment capital & maintenance costs | -1.4% | National, more pronounced in Southern Italy | Long term (≥ 4 years) | (~) % Impact on CAGR Forecast:-1.4% | Geographic Relevance:National, more pronounced in Southern Italy | Impact Timeline:Long term (≥ 4 years) |
Mo-99 / Tc-99m supply bottlenecks Mo-99 / Tc-99m supply bottlenecks | -1.1% | National impact with regional mitigation strategies | Short term (≤ 2 years) | |||
Radiation-dose safety & regulatory scrutiny Radiation-dose safety & regulatory scrutiny | -0.8% | National, with AIFA and ISS oversight | Medium term (2-4 years) | |||
Emerging photon-counting CT substitution risk Emerging photon-counting CT substitution risk | -0.6% | Northern Italy early adoption, national expansion | Long term (≥ 4 years) | |||
| Source: Mordor Intelligence | ||||||
High Equipment Capital & Maintenance Costs
PET/CT platforms cost EUR 2-4 million and frequently require bunker upgrades, straining hospital budgets that already allocate nearly 77.45% of operational spending to facility management. Aging buildings—70% surpassing their designed 50-year lifecycle—magnify retrofit expenses, especially in Southern provinces with fewer tertiary centers. Maintenance contracts with multinational OEMs add long-term overhead, prompting some regions to defer scanner refresh cycles and rely on referral flows to Northern hubs.
Mo-99/Tc-99m Supply Bottlenecks
Italy conducts more than 600,000 examinations annually with technetium-99m, yet depends on aging European reactors such as Petten’s High Flux Reactor, whose outages disrupt tracer availability. ENEA’s SORGENTINA-RF pilot dissolves molybdenum in hydrogen peroxide to yield domestic 99mTc batches, but economic parity with generator supply remains elusive. National contingency protocols include cyclotron-based back-ups and cross-regional patient redistribution, yet high isotope cost persists as a limiting factor.
Segment Analysis
By Product: Equipment Dominance Drives Infrastructure Modernization
Equipment retained 63.55% Italy nuclear imaging market share in 2025 as hospitals prioritized PET/CT and SPECT/CT replacements to meet hybrid-imaging demand. Lombardy, Veneto, and Emilia-Romagna collectively host the densest scanner fleets, benefiting from consistent SSN reimbursements and regional budget surpluses. The radioisotope segment advances at a 6.75% CAGR, buoyed by expanding Ga-68 and Lu-177 pipelines that support theranostic protocols. Cyclotron-based production shortens supply chains and elevates the Italy nuclear imaging market size for isotopes, particularly as LARAMED scales multi-curie outputs. Northern laboratories integrate artificial-intelligence-driven QC systems to optimize batch scheduling and reduce waste, a practice expected to cascade nationwide.
Adoption of energy-efficient digital scanners tempers hospital utility overhead and aligns with EU Green Deal directives, strengthening capital-expenditure cases. Vendor service-as-a-subscription models further mitigate upfront cost, encouraging smaller Southern facilities to enter the modality mix, albeit at slower cadence. Continuous performance upgrades, such as extended axial field-of-view detectors, are forecast to keep equipment leading Italy nuclear imaging market revenues through 2031.
Note: Segment shares of all individual segments available upon report purchase
By Application: Oncology Leadership Amid Neurological Growth
Oncology anchored 38.30% of 2025 procedure revenue, reflecting wide guideline inclusion for PET/CT in staging breast, lung, colorectal, and prostate malignancies. Neurology shows the sharpest climb at 7.08% CAGR as dementia prevalence in Italy’s aging population lifts F-18 amyloid and tau tracer demand. Cardiology sustains baseline volumes via Tc-99m SPECT perfusion, while thyroid applications benefit from standardized PRRT protocols released by the Italian Association of Nuclear Medicine. The oncology segment leverages PSMA and FAPI tracer innovation, broadening theranostic grids and reinforcing its dominance in Italy nuclear imaging market revenues.
Clinical trials such as the ITALIAN study validate radiation-sparring imaging workflows, bolstering payer confidence and supporting wider reimbursement for newer tracers. Emerging fibrotic-activity tracers expand the “other applications” bucket, hinting at diversified future revenue streams but not yet shifting share lines materially.
By End User: Hospital Consolidation Versus Private Expansion
Hospitals controlled 71.76% of procedures and tracer purchases in 2025, cementing their role as the backbone buyer in the Italy nuclear imaging market size. Diagnostic imaging centers, however, race ahead with a 7.25% CAGR as private chains exploit gaps in Southern service coverage and capture outbound patient flows. Academic and research institutes underpin innovation pipelines, often partnering with OEMs for first-in-human tracer trials and next-generation detector evaluations.
Hospital mergers and regional hub-and-spoke models aim to rationalize high-complexity workloads, yet operational costs still exceed sustainable thresholds, nudging administrators toward outsourcing non-core nuclear medicine services to accredited private centers. The government’s “super hospitals” blueprint could rebalance geography but faces scrutiny over capital efficiency and timelines.
Note: Segment shares of all individual segments available upon report purchase
Geography Analysis
Northern Italy captures the lion’s share of equipment installations and isotopic manufacturing, aided by a cluster of institutions, including INFN Legnaro, CNAO Pavia, and the Trento Proton Center-that collectively shape the technical frontier. Bracco Imaging’s Milan headquarters and Siemens Healthineers’ PETNET facility in Ivrea round out a vertically integrated ecosystem stretching from drug substance to finished dose. Regional healthcare budgets support higher scanner density, Lombardy alone runs 97 acute hospitals, translating into broader access and lower wait times.
Central Italy taps strengths in academic research and regulatory stewardship from Rome, yet market penetration trails the North. AIFA’s presence fosters faster price-listing for innovative tracers, but capital investments remain lopsided. Southern Italy struggles with a 21.3% escape index for complex imaging, reflecting patient migration northward for advanced care. Government-approved pharmaceutical plant expansions in Torre Annunziata and SEZ fiscal incentives aim to seed a nucleus for future nuclear medicine growth, but scanner deployment still lags.
Proton therapy exemplifies geographic imbalance: all three operational centers are Northern, leaving head-and-neck patients in the South reliant on cross-regional referrals, a gap current capacities fail to bridge. Although new “super hospital” proposals could mitigate disparities, financing and staffing hurdles temper near-term forecasts. Overall, regional divergence remains a structural feature shaping procurement cycles, utilization rates, and ultimately the Italy nuclear imaging market.
Reports are available across multiple geographies.
Gain in-depth market insights across regions to support informed decisions.
Competitive Landscape
Market Concentration
The Italy nuclear imaging market features moderate consolidation as capital intensity and regulatory barriers curb entrant numbers. Multinationals such as Siemens Healthineers, GE HealthCare, and Bracco Imaging dominate equipment and tracer supply, sustained by global manufacturing scale and deep IP portfolios. Siemens’ USD 223 million acquisition of Novartis’s Advanced Accelerator Applications Molecular Imaging in December 2024 expanded its European radiopharmacy network to 13 sites, bolstering PET tracer reach across Italy. GE HealthCare’s full takeover of Nihon Medi-Physics in March 2025 underscores plans to integrate tracer production with scanner analytics and cloud platforms.
Domestic incumbent Bracco Imaging continues to allocate more than 10% of revenue to R&D and now controls over 1,500 patents, positioning itself as a global force in contrast media and precision diagnostics. White-space opportunity persists in local cyclotron networks and Southern infrastructure upgrades, arenas where regional players and public-private consortia could carve share. Artificial-intelligence-enabled workflow tools—spanning dose optimization to lesion detection—add another layer of differentiation, invigorating competition beyond hardware specs.
Start-ups and midsize firms gain footing through theranostic niches; Curium’s March 2025 purchase of Monrol amplifies Lu-177 capacity, an isotope pivotal to prostate and neuroendocrine tumor therapy. Meanwhile, Blue Earth Therapeutics secured USD 77 million to advance PSMA-targeted candidates, enriching the innovation pipeline. Overall, supplier strategies converge on end-to-end service models that fuse scanners, tracers, and analytics, intensifying rivalry and raising switching costs for Italian providers.
Italy Nuclear Imaging Industry Leaders
*Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- September 2024: The Italian government authorized Novartis's EUR 80 million pharmaceutical plant expansion in Torre Annunziata, Southern Italy, targeting enhanced production volumes for new pharmaceuticals and improved packaging efficiency by 2025
- November 2024: Bracco Imaging, headquartered in Milan, invested EUR 80 million in the new Hexagon manufacturing facility in Switzerland to triple production capacity of contrast agents for ultrasound imaging, enhancing the Italian company's global supply capabilities for precision medicine applications
Table of Contents for Italy Nuclear Imaging Industry Report
1. Introduction
- 1.1Study Assumptions & Market Definition
- 1.2Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Landscape
- 4.1Market Overview
- 4.2Market Drivers
- 4.2.1Rising incidence of cancer & CVD
- 4.2.2Growing adoption of hybrid PET/CT & SPECT/CT
- 4.2.3Favorable reimbursement framework (SSN tariffs)
- 4.2.4Increase in public-private investment for nuclear-medicine suites
- 4.2.5Expansion of theranostic radioisotope production in Northern Italy
- 4.2.6Adoption of cyclotron-based Ga-68 generators in regional radiopharmacies
- 4.3Market Restraints
- 4.3.1High equipment capital & maintenance costs
- 4.3.2Mo-99 / Tc-99m supply bottlenecks
- 4.3.3Radiation-dose safety & regulatory scrutiny
- 4.3.4Emerging photon-counting CT substitution risk
- 4.4Value / Supply-Chain Analysis
- 4.5Regulatory Landscape
- 4.6Technological Outlook
- 4.7Porter’s Five Forces
- 4.7.1Bargaining Power of Suppliers
- 4.7.2Bargaining Power of Buyers
- 4.7.3Threat of New Entrants
- 4.7.4Threat of Substitutes
- 4.7.5Competitive Rivalry
5. Market Size & Growth Forecasts (Value)
- 5.1By Product (Value)
- 5.1.1Equipment
- 5.1.2Radioisotopes
- 5.1.2.1SPECT Radioisotopes
- 5.1.2.1.1Technetium-99m (Tc-99m)
- 5.1.2.1.2Thallium-201 (Tl-201)
- 5.1.2.1.3Gallium-67 (Ga-67)
- 5.1.2.1.4Iodine-123 (I-123)
- 5.1.2.1.5Other SPECT Isotopes
- 5.1.2.2PET Radioisotopes
- 5.1.2.2.1Fluorine-18 (F-18)
- 5.1.2.2.2Rubidium-82 (Rb-82)
- 5.1.2.2.3Other PET Isotopes
- 5.2By Application (Value)
- 5.2.1Cardiology
- 5.2.2Neurology
- 5.2.3Thyroid
- 5.2.4Oncology
- 5.2.5Other Applications
- 5.3By End User (Value)
- 5.3.1Hospitals
- 5.3.2Diagnostic Imaging Centres
- 5.3.3Academic & Research Institutes
6. Competitive Landscape
- 6.1Market Concentration
- 6.2Market Share Analysis
- 6.3Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
- 6.3.1GE HealthCare
- 6.3.2Siemens Healthineers
- 6.3.3Advanced Accelerator Applications (Novartis)
- 6.3.4Koninklijke Philips N.V.
- 6.3.5Curium Pharma
- 6.3.6Cardinal Health Inc.
- 6.3.7Bracco Imaging S.p.A.
- 6.3.8Telix Pharmaceuticals Ltd.
- 6.3.9Alliance Medical (Life Healthcare Group)
- 6.3.10Advanced Accelerator Applications S.A. (Novartis)
- 6.3.11NTP Radioisotopes
7. Market Opportunities & Future Outlook
- 7.1White-space & Unmet-Need Assessment
Italy Nuclear Imaging Market Report Scope
As per the scope of the report, nuclear medicine imaging procedures are non-invasive, with the exception of intravenous injections, and are usually painless medical tests that help physicians diagnose and evaluate medical conditions. These imaging scans use radioactive materials called radiopharmaceuticals or radiotracers. These radiopharmaceuticals are used in diagnosis and therapeutics. They are small substances that contain a radioactive substance that is used in the treatment of cancer, cardiac and neurological disorders. Italy Nuclear Imaging Market is segmented by Product (Equipment, and Diagnostic Radioisotope (SPECT Radioisotopes, and PET Radioisotopes), Application (SPECT Application (Cardiology, Neurology, Thyroid, and Other SPECT Applications), and PET Application (Oncology, Cardiology, Neurology, and Other PET Applications). The report offers the value (in USD million) for the above segments.
